FDA Greenlights Acepodia’s Investigational ADC Candidate ACE723 for Advanced Liver Cancer Trial

As reported on PharmaBiz, the US Food and Drug Administration (FDA) has authorized Acepodia to proceed with clinical testing of ACE723, an investigational antibody-drug conjugate (ADC) designed for patients with…

Continue Reading FDA Greenlights Acepodia’s Investigational ADC Candidate ACE723 for Advanced Liver Cancer Trial

Roche-Partnered B7-H3 ADC Meets Phase 3 Endpoint in Small Cell Lung Cancer, Shows Competitive Safety Profile

As reported on Fierce BioTech, a phase 3 study conducted by MediLink has delivered positive results for Roche-partnered antibody-drug conjugate (ADC) tambotatug pelitecan (tam-peli), also known as YL201, in patients…

Continue Reading Roche-Partnered B7-H3 ADC Meets Phase 3 Endpoint in Small Cell Lung Cancer, Shows Competitive Safety Profile